India markets open in 2 hours 10 minutes
  • BSE SENSEX

    48,732.55
    +41.75 (+0.09%)
     
  • Nifty 50

    14,677.80
    -18.70 (-0.13%)
     
  • Dow

    34,382.13
    +360.73 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.98 (+2.32%)
     
  • BTC-INR

    3,303,265.50
    -198,027.25 (-5.66%)
     
  • CMC Crypto 200

    1,246.99
    -111.57 (-8.21%)
     
  • Hang Seng

    28,130.51
    +102.94 (+0.37%)
     
  • Nikkei

    28,005.97
    -78.50 (-0.28%)
     
  • EUR/INR

    88.9110
    -0.0649 (-0.07%)
     
  • GBP/INR

    103.1644
    -0.0593 (-0.06%)
     
  • AED/INR

    19.8930
    0.0000 (0.00%)
     
  • INR/JPY

    1.4900
    -0.0003 (-0.02%)
     
  • SGD/INR

    54.8850
    -0.0810 (-0.15%)
     

Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

The pre-recorded presentation will be made available under the "Investors and Media" section of Seres’ website on Thursday, April 22, 2021 at 8:00 a.m. ET and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005172/en/

Contacts

PR Contact
Kristin Ainsworth
kainsworth@serestherapeutics.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com